Bristol-Myers Squibb Company Company Profile (NYSE:BMY)

About Bristol-Myers Squibb Company (NYSE:BMY)

Bristol-Myers Squibb Company logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:BMY
  • CUSIP: 11012210
  • Web:
  • Market Cap: $105.25 billion
  • Outstanding Shares: 1,639,926,000
Average Prices:
  • 50 Day Moving Avg: $62.78
  • 200 Day Moving Avg: $56.98
  • 52 Week Range: $46.01 - $66.10
  • Trailing P/E Ratio: 23.44
  • Foreward P/E Ratio: 20.12
  • P/E Growth: 2.07
Sales & Book Value:
  • Annual Revenue: $20.24 billion
  • Price / Sales: 5.20
  • Book Value: $8.96 per share
  • Price / Book: 7.16
  • Annual Dividend: $1.56
  • Dividend Yield: 2.4%
  • EBITDA: $6.01 billion
  • Net Margins: 22.66%
  • Return on Equity: 32.33%
  • Return on Assets: 14.86%
  • Debt-to-Equity Ratio: 0.47%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.45%
  • Average Volume: 6.05 million shs.
  • Beta: 1.19
  • Short Ratio: 2.45

Frequently Asked Questions for Bristol-Myers Squibb Company (NYSE:BMY)

What is Bristol-Myers Squibb Company's stock symbol?

Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company declared a quarterly dividend on Wednesday, September 13th. Stockholders of record on Friday, October 6th will be paid a dividend of $0.39 per share on Wednesday, November 1st. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.43%. The ex-dividend date is Thursday, October 5th. View Bristol-Myers Squibb Company's Dividend History.

How were Bristol-Myers Squibb Company's earnings last quarter?

Bristol-Myers Squibb Company (NYSE:BMY) issued its quarterly earnings data on Thursday, July, 27th. The company reported $0.74 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts' expectations of $5.09 billion. Bristol-Myers Squibb Company had a net margin of 22.66% and a return on equity of 32.33%. The firm's revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.69 earnings per share. View Bristol-Myers Squibb Company's Earnings History.

When will Bristol-Myers Squibb Company make its next earnings announcement?

Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Bristol-Myers Squibb Company.

What guidance has Bristol-Myers Squibb Company issued on next quarter's earnings?

Bristol-Myers Squibb Company issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.94.

Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?

17 equities research analysts have issued twelve-month target prices for Bristol-Myers Squibb Company's shares. Their predictions range from $49.00 to $75.00. On average, they expect Bristol-Myers Squibb Company's stock price to reach $62.08 in the next year. View Analyst Ratings for Bristol-Myers Squibb Company.

What are analysts saying about Bristol-Myers Squibb Company stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:

  • 1. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
  • 2. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
  • 3. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)

Who are some of Bristol-Myers Squibb Company's key competitors?

Who are Bristol-Myers Squibb Company's key executives?

Bristol-Myers Squibb Company's management team includes the folowing people:

  • Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer
  • Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations
  • Louis S. Schmukler, President - Global Manufacturing and Supply
  • Ann Powell Judge, Chief Human Resource Officer, Senior Vice President
  • Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer
  • Sandra Leung, Executive Vice President, General Counsel
  • Murdo Gordon, Executive Vice President, Chief Commercial Officer
  • Paul von Autenried, Senior Vice President, Chief Information Officer
  • Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer
  • Joseph C. Caldarella, Senior Vice President, Corporate Controller

Who owns Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Beacon Financial Group (0.01%), Osborn Williams & Donohoe LLC (0.00%), Eqis Capital Management Inc. (0.00%), Bridges Investment Counsel Inc. (0.00%), Bridges Investment Management Inc. (0.00%) and Curbstone Financial Management Corp (0.00%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Company.

Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., Osborn Williams & Donohoe LLC, Bridges Investment Counsel Inc. and Eqis Capital Management Inc.. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Company.

Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp, McQueen Ball & Associates Inc., Stillwater Investment Management LLC, Beacon Financial Group and Bridges Investment Management Inc.. View Insider Buying and Selling for Bristol-Myers Squibb Company.

How do I buy Bristol-Myers Squibb Company stock?

Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb Company's stock price today?

One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $64.18.

MarketBeat Community Rating for Bristol-Myers Squibb Company (NYSE BMY)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  655 (Vote Outperform)
Underperform Votes:  625 (Vote Underperform)
Total Votes:  1,280
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $62.08 (3.27% downside)
Consensus Price Target History for Bristol-Myers Squibb Company (NYSE:BMY)
Price Target History for Bristol-Myers Squibb Company (NYSE:BMY)
Analysts' Ratings History for Bristol-Myers Squibb Company (NYSE:BMY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Jefferies Group LLCDowngradeBuy -> Hold$72.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetEqual Weight$58.00 -> $65.00N/AView Rating Details
10/12/2017BMO Capital MarketsSet Price TargetSell$49.00N/AView Rating Details
9/19/2017Cowen and CompanyReiterated RatingHold$65.00LowView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy -> Neutral$65.00LowView Rating Details
9/8/2017Credit Suisse GroupReiterated RatingNeutral -> HoldLowView Rating Details
9/7/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$62.00 -> $65.00LowView Rating Details
7/28/2017Leerink SwannLower Price TargetOutperform$66.00 -> $61.00LowView Rating Details
7/27/2017Piper Jaffray CompaniesSet Price TargetHold$60.00MediumView Rating Details
7/17/2017Deutsche Bank AGSet Price TargetHold$54.00 -> $55.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/21/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
11/8/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
10/10/2016SunTrust Banks, Inc.Reiterated RatingHold$68.00 -> $62.00N/AView Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldN/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00N/AView Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$0.75N/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.09 billion$5.14 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb Company (NYSE:BMY)
2017 EPS Consensus Estimate: $2.83
2018 EPS Consensus Estimate: $3.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.70$0.72$0.71
Q2 20173$0.70$0.76$0.73
Q3 20174$0.70$0.78$0.74
Q4 20173$0.62$0.68$0.65
Q1 20181$0.74$0.74$0.74
Q2 20181$0.75$0.75$0.75
Q3 20181$0.78$0.78$0.78
Q4 20181$0.81$0.81$0.81
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb Company (NYSE:BMY)
Next Dividend:11/1/2017
Annual Dividend:$1.56
Dividend Yield:2.43%
Dividend Growth:2.80% (3 Year Average)
Payout Ratio:56.73% (Trailing 12 Months of Earnings)
52.35% (Based on This Year's Estimates)
48.90% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Dividend History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.84%
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.00View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.00View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.00View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.84View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.00View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bristol-Myers Squibb Company (NYSE:BMY)
Latest Headlines for Bristol-Myers Squibb Company (NYSE:BMY)
DateHeadline logoBristol-Myers Gets Priority Review for Opdivo Label Expansion - October 17 at 5:27 PM logoUS Pharma Mergers and Acquisitions in 3Q17 - October 17 at 5:27 PM logoBrokers Set Expectations for Bristol-Myers Squibb Company's Q3 2017 Earnings (BMY) - October 17 at 7:48 AM logoBristol-Myers Stock May Have Exhausted Its Upside For Now - October 16 at 10:25 PM logoBRIEF-FDA accepts Bristol-Myers Squibb’s application for Opdivo - October 16 at 10:25 PM logoNoteworthy Monday Option Activity: FCX, BMY, BIIB - Nasdaq - October 16 at 5:24 PM logoJefferies Downgrades Bristol-Myers Squibb Co. (BMY) to Hold - - October 16 at 5:24 PM logoCorporate News Blog - Bristol-Myers Squibb's Opdivo to be Available for Head and Neck Cancer Patients in UK - October 16 at 5:24 PM logo[$$] Bristol-Myers Gets a Boost - October 16 at 5:24 PM logoMorning Movers: Nordstrom Tumbles, Adobe Drops, Bristol-Myers Slips - October 16 at 5:24 PM logoWhat Goes Up….Is Bristol-Myers a $48 Stock? - October 16 at 5:24 PM logoU.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review - October 16 at 5:24 PM logoBRIEF-Bristol-Myers ‍announces data for Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer - October 16 at 4:53 AM logoBristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts - October 16 at 4:53 AM logoOpdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032 - October 16 at 4:53 AM logoBristol-Myers Squibb Company (BMY) Given a $49.00 Price Target at BMO Capital Markets - October 15 at 11:26 AM logoLightning Round: Jim Cramer Weighs In On Bristol-Myers Squibb, Mazor Robotics And More - October 14 at 9:29 PM logoLightning Round: Cramer Weighs In On Bristol-Myers Squibb, Mazor ... - Benzinga - October 13 at 10:19 PM logoBristol-Myers Squibb (BMY) Extends Strategic Partnership with ... - PR Newswire (press release) - October 13 at 10:19 PM logoBristol-Myers Squibb Company (BMY) PT Raised to $65.00 at Barclays PLC - October 13 at 7:02 PM logoBristol-Myers Squibb (BMY) Reports Extension of Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH - October 13 at 5:18 PM logoBristol-Myers (BMY), TARGET Extend Partnership for NASH Study - October 13 at 5:18 PM logoBRIEF-Bristol-Myers Squibb extends strategic partnership with Target Pharmasolutions - October 12 at 10:31 PM logoBristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH - October 12 at 5:27 PM logoBristol-Myers Squibb Company (BMY) Upgraded to "Buy" at Vetr Inc. - October 10 at 12:38 AM logoBristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine - October 9 at 5:25 PM logoIs Bristol-Myers Squibb Company’s (BMY) ROE Of 30.51% Sustainable? - October 9 at 5:25 PM logoInvestors Are Scooping Up Shares of Apple, Ditching Bristol Myers and Pfizer - October 9 at 5:25 PM logoBristol-Myers Squibb Co. (BMY) PT Raised to $72 at UBS; 'Shares Reflect Modest Value for Potential Positive Data for ... - - October 8 at 3:14 AM logoBristol-Myers Squibb's (BMY) "Buy" Rating Reaffirmed at UBS AG - October 7 at 2:58 PM logoBristol-Myers Squibb Sees Unusually High Options Volume (BMY) - October 7 at 3:50 AM logoBristol-Myers Squibb Co (BMY) Stock Raised to Hold - - October 6 at 4:55 PM logoBristol-Myers Squibb Won't Be Left Behind in This Bull Market -- Jim Cramer - October 6 at 4:55 PM logoMissing Link: Long Capital One, Bristol-Myers - October 6 at 4:55 PM logoBristol-Myers Squibb Co (BMY) Stock Raised to Hold - October 6 at 11:17 AM logoHow Important Is Eliquis For Bristol-Myers Squibb? - October 5 at 7:48 PM logoCaregivers Wish Liver Cancer Received Greater Public Awareness in the U.S., New Survey Reveals - October 5 at 7:48 PM logoStillwater Investment Management, LLC Buys DowDuPont Inc, Bristol-Myers Squibb Company - October 5 at 7:48 PM logoBristol-Myers Squibb: Now Is Not The Time - Seeking Alpha - October 5 at 2:46 PM logoBristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 05, 2017 - Nasdaq - October 4 at 1:09 PM logoBristol-Myers Squibb Named Top Dividend Stock With Insider Buying and 2.45% Yield (BMY) - October 2 at 6:32 PM logoBristol-Myers Squibb Company (BMY) Raised to Buy at Vetr Inc. - October 1 at 3:54 PM logoInvestors Buy Large Volume of Bristol-Myers Squibb Put Options (BMY) - October 1 at 2:16 AM logoBristol-Myers Squibb Company (BMY) Receives Average Recommendation of "Hold" from Brokerages - September 30 at 6:36 PM logoHead-To-Head Survey: Bristol-Myers Squibb (BMY) & Its Competitors - September 30 at 4:32 AM logoUNC lands $1.7M grant from Bristol-Myers Squibb - September 29 at 3:52 PM logoQ1 2018 EPS Estimates for Bristol-Myers Squibb Company (BMY) Decreased by Analyst - September 29 at 9:08 AM logoVetr Inc. Lowers Bristol-Myers Squibb Company (BMY) to Hold - September 29 at 12:44 AM logoGlobal Oncology Market 2017-2023 Featuring AstraZeneca, Bristol-Myers Squibb, Celgene, Novartis, Pfizer & Roche - September 28 at 4:52 PM logoStrategy To YieldBoost Bristol-Myers Squibb Co. From 2.5% To 7.2% Using Options - September 28 at 4:52 PM



Bristol-Myers Squibb Company (BMY) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.